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Abstract As the number of cancer survivors grows,
prediction of radiotherapy-induced second cancer risks
becomes increasingly important. Because the latency per-
iod for solid tumors is long, the risks of recently introduced
radiotherapy protocols are not yet directly measurable. In
the accompanying article, we presented a new biologically
based mathematical model, which, in principle, can esti-
mate second cancer risks for any protocol. The novelty of
the model is that it integrates, into a single formalism,
mechanistic analyses of pre-malignant cell dynamics on
two different time scales: short-term during radiotherapy
and recovery; long-term during the entire life span. Here,
we apply the model to nine solid cancer types (stomach,
lung, colon, rectal, pancreatic, bladder, breast, central
nervous system, and thyroid) using data on radiotherapy-
induced second malignancies, on Japanese atomic bomb
survivors, and on background US cancer incidence.
Potentially, the model can be incorporated into radiother-
apy treatment planning algorithms, adding second cancer
risk as an optimization criterion.
Introduction
Ionizing radiation is a well-known cytotoxic and carcin-
ogenic agent. As such, it is effective as a treatment for
cancer, but can also induce secondary malignancies
(Travis et al. 1996, 1997, 2002, 2003, 2005; van Leeuwen
et al. 2003). As more patients undergo cancer radiother-
apy and live longer after treatment, the number of cancer
survivors has tripled over the past three decades and
continues to increase, reaching more than 10 million in
the US (Editorial 2004). The lifetime risk of radiation-
induced second cancers in these individuals is not negli-
gible (e.g. Brenner et al. 2007), and these second cancers
can result in high mortality and morbidity—for example,
breast cancer radiotherapy can cause lung cancer (see
below), and lung cancer has a poor prognosis. Conse-
quently, second malignancies induced by radiotherapy are
becoming a growing concern (Brenner et al. 2000; Ron
2006). This is the case particularly for patients irradiated
in childhood, who have a long life expectancy during
which second cancers can develop, and in whom the
relative risk of some radiogenic second cancers is on the
order of 10–100 (Ron 2006; Ronckers et al. 2006; Neglia
et al. 2006).
It has only recently become apparent (Lindsay et al.
2001; Sachs and Brenner 2005) that even at high radiation
doses—tens of Gy—radiation-induced cancer risk remains
substantial, presumably due to cellular repopulation,
instead of dropping essentially to zero due to cell inacti-
vation (killing), as was previously thought (Bennett et al.
2004; Dasu et al. 2005). Thus, tissues surrounding the
tumor, which unavoidably receive doses not much smaller
than the prescribed treatment dose, may be a source of
much of the second cancer risk attributable to radiotherapy
(Hodgson et al. 2007; Koh et al. 2007).
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second cancers would be to compare radiotherapy proto-
cols of equal efﬁcacy against the primary tumor, and
identify the ones with the lowest second cancer risk.
However, because the latency period for radiation-induced
solid tumors is long (e.g. Tokunaga et al. 1979; Brenner
et al. 2000; Ivanov et al. 2004, 2009), the carcinogenic
effects of radiotherapy have been directly measured only
for regimens used several decades ago. The risks that may
be associated with newer treatment methods are for the
most part not yet observable. Biologically motivated
mathematical/computational models, calibrated using data
from older protocols, can address this problem by pre-
dicting risks of current/prospective treatment regimens.
In the accompanying article (Shuryak et al. 2009), such a
model is presented. To our knowledge, the model is the ﬁrst
comprehensive attempt to integrate a detailed analysis of
pre-malignant cell dynamics during the comparatively short
period of radiotherapy with a long-term model of carcino-
genesis over the entire human life span. By comparison,
existing models either emphasize the long-term processes
andmakesimplisticassumptionsabout short-termones(e.g.
ArmitageandDoll1954;Moolgavkar1978,1980;Armitage
1985; Moolgavkar and Luebeck 2003), or vice versa (e.g.
Upton 2003; Sachs and Brenner 2005; Shuryak et al. 2006;
Sachs et al. 2007). A formalism that integrates both time
scales is advantageous in terms of biological realism and
should increase the accuracy of predictions.
In the accompanying article, the focus was on biological
assumptions and mathematical implementation. Here, we
apply our model speciﬁcally to the task of predicting
radiotherapy-induced cancers, using second cancer data for
nine solid cancer types—stomach, lung, colon, rectal,
pancreatic, bladder, breast, CNS (central nervous system),
and thyroid—in patients treated by radiotherapy for various
primary cancers. Some of the model parameters are
obtained from ﬁtting radiogenic risks at comparatively low
doses for Japanese atomic bomb survivors, or from back-
ground US cancer incidence data.
Materials and methods
Model
The model used emphasizes initiation, either by radiation
or by spontaneous processes, of normal stem cells to
produce pre-malignant stem cells, the cell kinetics of
pre-malignant stem cells, and their transformation into
malignant cells; it assumes the pre-malignant (i.e. initiated)
cells to reside in stem cell niches or compartments, referred
to generically as ‘‘niches’’; and it emphasizes those niches
that are ‘‘fully pre-malignant’’, i.e. containing as many pre-
malignant stem cells as the niche carrying capacity allows.
The model uses a total of 11 parameters, which were
introduced in Table 1 of the accompanying article (Shuryak
et al. 2009). Three parameters, which characterize spon-
taneous stem cell initiation and subsequent malignant
transformation (a, units = time
-2), pre-malignant niche
replication (b, units = time
-1), and age-dependent stem
cell senescence (c, units = time
-2), can be determined
with relatively high precision from background cancer
incidence. Seven other parameters describe radiation-rela-
ted effects: constants X (units = time 9 dose
-1) and Y
(units = dose
-1) characterizing the dose-dependences of
initiation and promotion, respectively; a parameter for
homeostatic regulation of the number of pre-malignant
stem cells per niche d (units = time
-1); the carrying
capacity, Z (units = cells 9 niche
-1), for the number of
pre-malignant stem cells in a niche; the stem cell radiation-
inactivation constants a (units = dose
-1) and b (units =
dose
-2); and the maximum net stem cell repopulation rate
Table 1 Best-ﬁt parameter values for background incidence of all analyzed cancer types
Cancer Sex a 9 10
-8 (years
-2) b (years
-1) c 9 10
-3 (years
-2)
Stomach M 0.402 (0.380, 0.425) 0.222 (0.219, 0.226) 1.10 (1.08, 1.14)
Lung M 0.00291 (0.0028, 0.0030) 0.460 (0.459, 0.462) 2.91 (2.89, 2.92)
Colon M 1.78 (1.57, 2.10) 0.204 (0.197, 0.208) 0.944 (0.892, 0.985)
Rectum M 1.01 (0.852, 1.49) 0.217 (0.201, 0.224) 1.23 (1.09, 1.28)
Pancreas M 0.0732 (0.0397, 0.255) 0.293 (0.156, 0.315) 1.67 (0.174, 1.85)
Bladder M 0.0600 (0.0600, 0.0601) 0.282 (0.279, 0.283) 1.54 (1.51, 1.56)
Breast F 58.1 (55.6, 60.2) 0.199 (0.197, 0.201) 1.35 (1.34, 1.37)
CNS Both 0.243 (0.230, 0.259) 0.257 (0.254, 0.260) 1.66 (1.61, 1.68)
Thyroid Both 120 (105, 124) 0.0768 (0.0740, 0.0872) 0.669 (0.646, 0.770)
Parameter interpretations are: a proportionality constant for spontaneous stem cell initiation, b pre-malignant niche replication rate, c age-
dependent pre-malignant stem cell senescence constant
The numbers in parentheses represent the 95% conﬁdence intervals for the corresponding parameter
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123k (units = time
-1). The last parameter—the lag period
from the appearance of the ﬁrst fully malignant cell until
development of cancer, L (units = time)—can be esti-
mated from the literature.
The equation for the mean expected number of new fully
malignant cells per individual per year under background
conditions (Abac, units = time
-1), which is an approxima-
tion for the cancer incidence hazard function L years later,
was derived in the previous article. It is repeated below,
using the notation where age is deﬁned as the sum of age at
exposure (Tx) and the time after exposure (Ty):
Abac ¼ð a=bÞðexp½bðTx þ TyÞ    1Þexp½ cðTx þ TyÞ
2 
ðEq: 6inShuryaketal:2009Þ
For data ﬁtting, the exact hazard deﬁned as H =
A/(1  
R t
0 Adu) is used, but we use the simpler expression
forAintheequationsbelow,keepinginminditsinterpretation
and limitations.
The expression for the radiogenic excess relative risk
(ERR) was also derived previously and is repeated below,
where D is the total radiation dose, Sf(Z, D) is the proba-
bility that a pre-existing fully pre-malignant niche survives
radiation, i.e. that not all the pre-malignant stem cells in the
niche are inactivated, and ISf(D) (units = dose) represents
a net outcome of initiation, inactivation, and cell repopu-
lation (iir) during radiation exposure:
ERR ¼½ ð Q1Q2 þ Q3Þ=Q4  1; where
Q1 ¼ð 1 þ YDÞ=½1 þ YDð1   exp½ dTy Þ ;
Q2 ¼½ ð exp½bTx  1ÞSfðZ;DÞþbX ISfðDÞ exp½bT y ;
Q3 ¼ exp½bT y  1; Q4 ¼ exp½bðTx þ TyÞ    1
ðEq:15inShuryaketal:2009Þ
For a single-dose acute exposure, where there is no cell
repopulation during irradiation, the functions ISf(D) and
Sf(Z, D) simplify to the following expressions: Sf(Z, D) =
1 - (1 - exp[–aD - bD
2])
Z and ISf(D) = D exp[–aD -
bD
2]. For multi-fraction radiotherapy protocols, where
substantial repopulation occurs between dose fractions,
these functions are evaluated by the stochastic process
formalism described in detail in the previous article.
As noted in the previous article, the term Q2 in Eq. 15 of
(Shuryak et al. 2009) is proportional to the number of fully
pre-malignant stem cell niches shortly after exposure; Q1 is
the normalized size of such a niche, which can differ from
the background carrying capacity Z due to radiation-pro-
motion effects; Q3 is proportional to the number of new
niches spontaneously initiated, after exposure/recovery, by
endogenous processes independent of radiation; and Q4 is
proportional to the total number of fully pre-malignant
niches under background conditions. The parameters a and
c cancel out of the ERR expression.
Data used
Here the model is applied by ﬁtting it to data on nine
cancer types: stomach, lung, colon, rectal, pancreatic,
bladder, breast, CNS, and thyroid. These particular types
were selected because for them radiation-induced ERR
data are available both at comparatively low doses (ERR/
Gy estimates based on Japanese atomic bomb survivors)
and at high doses—second cancer ERRs estimated for
patients treated with radiotherapy for existing malignan-
cies, with at least two different high-dose points. There is a
large body of second cancer data, and detailed comparisons
to data on the atomic bomb survivors have been made
previously (e.g. Little 2001). For our present purposes, the
multiple dose points criterion for second cancer data was
important because the analysis presented here was inten-
tionally focused on modeling the shape of the radiation
dose response at high doses.
The low-dose ERR/Gy estimates at attained age 70 and
various ages at exposure were taken from an analysis of
atomic bomb survivors by Preston et al. (2007), Tables 11
and 12. Gender-averaged ERR/Gy numbers were adjusted
by sex-speciﬁc incidence ratios provided by the same
authors. We used these particular ERR estimates because
they approximate lifetime risk, were adjusted for several
potentialconfoundingvariables,andwere based onthemost
recent version of individual radiation dose calculations.
An important goal of our model development is second
cancer risk estimation in Western populations. Conse-
quently, we ﬁtted the model to background incidence data
for the selected cancers in the US, using the Surveillance
Epidemiology and End Results (SEER) database (http://
seer.cancer.gov), instead of using the incidence data from
Japan provided by the Radiation Effects Research Foun-
dation (RERF) (http://www.rerf.or.jp/). This raised the
issue of risk transfer between the Japanese and Western
populations. For simplicity, we used the fully multiplica-
tive approach by directly transferring the ERR. Adequate
ﬁts were obtained (see below), which suggests the direct
ERR transfer to be adequate for the present purpose and for
the cancer types chosen, at least as a ﬁrst approximation.
The high-dose radiotherapy-induced ERRs were taken
from the following data sets which are, we believe, rep-
resentative of currently available comprehensive second
cancer epidemiologic studies that considered more than
one dose:
• Separate ERRs for bladder, colon, rectal, pancreatic,
and stomach cancers reported from a case–control
study embedded in a cohort of 28,843 patients, who
were treated with radiotherapy for testicular cancer and
survived for at least 1 year (Travis et al. 1997, 2005).
The patients were gathered from 16 population-based
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123tumor registries in North America and Europe. The
mean age at radiotherapy was approximately 35 years,
and the mean latency time before second cancer
diagnosis was 18 years. Over 3,300 patients survived
for more than 20 years. The particular ﬁve cancer types
listed above were selected because they showed the
most substantial radiation-induced ERRs, whereas the
risk patterns for other cancer types, e.g. prostate,
analyzed by the same studies were less clear. The data
were transcribed from Table 3 in (Travis et al. 1997). A
dose response could be constructed because radiother-
apy regimens for non-seminoma testicular cancer
typically involved a twofold higher dose, given in
twice as many fractions, compared with regimens for
seminoma testicular cancer [see Appendix Table 1 in
(Travis et al. 1997)]. Error bars (95% CI) were
estimated using Poisson assumptions about the distri-
bution of cancer cases.
• Separate ERRs for breast and lung cancers reported in
patients treated with radiotherapy for Hodgkin’s dis-
ease (Travis et al. 2002, 2003; van Leeuwen et al. 2003;
Gilbert et al. 2003). The breast cancer data were
obtained from a case–control study within a cohort of
3,817 female patients, who were diagnosed with
Hodgkin’s disease at an age of \30 years (mean age
at radiotherapy = 22 years) in North America and
Europe, and survived for at least 1 year after radio-
therapy (mean latency time before second cancer
diagnosis = 18 years) (Travis et al. 2003); and from
another study of 650 patients treated for Hodgkin’s
disease at an age of\41 years (mean age at radiother-
apy = 21 years) in the Netherlands, who survived for
at least 5 years (mean latency time before second
cancer diagnosis = 18 years) (van Leeuwen et al.
2003). The lung cancer data were obtained from a
case–control study within a cohort of 19,046 Hodgkin’s
disease patients diagnosed in North America and
Europe, who survived for at least 1 year after radio-
therapy (Travis et al. 2002). The mean age at
radiotherapy was 48 years, and the mean latency time
before second cancer diagnosis was 11 years. Addi-
tional lung cancer data were obtained from another
case–control study within the same cohort (Gilbert
et al. 2003). The mean age at radiotherapy was
46 years, and the mean latency time before second
cancer diagnosis was 8 years. In both lung cancer
studies, the subjects were predominantly males, current
or former tobacco smokers.
• ERR for thyroid cancer reported from a case-control
study within a cohort of 14,054 patients of both sexes,
treated for various cancer types in childhood in North
America, who survived for at least 5 years (Ronckers
et al. 2006). The mean age at radiotherapy was
10 years, and the mean latency time before second
cancer diagnosis was 15 years.
• ERRs for CNS cancers, also reported from a case–
control study within a cohort of 14,361 patients of both
sexes, treated for various cancer types in childhood in
North America, who survived for at least 5 years
(Neglia et al. 2006). The mean age at radiotherapy was
5 years, and the mean latency time before second
cancer diagnosis was 10 years. The glioma and menin-
gioma data were pooled in our analysis.
Parameter estimation and data ﬁtting procedure
Fitting of the model to the data was carried out using a
customized random-restart simulated annealing algorithm
implemented in the FORTRAN language (Press 1989).
Standard least-squares inverse variance techniques were
used for weighting individual data points.
To reduce the number of adjustable parameters, the stem
cell inactivation (a and b) and repopulation (k) constants
were restricted to biologically plausible values for each
cancer type, based on the literature (Bentzen et al. 1996;
Challeton et al. 1997; Thames et al. 1989; Thames et al.
1990; Shimomatsuya et al. 1991; Rew and Wilson 2000;
Fowler 2001; Chen et al. 2006; Ogawa et al. 2006; Phillips
et al. 2006; Rachidi et al. 2007; Williams et al. 2008). The
lag period from the appearance of the ﬁrst fully malignant
cell until development of cancer, L, was set at 10 years,
which is consistent with available data (e.g. Brenner et al.
2000; Tokunaga et al. 1979; Ivanov et al. 2004).
The ﬁtting procedure consisted of two sequential steps:
1. First, the expression for the background cancer hazard
H was ﬁtted to age- and sex-dependent US background
cancer incidence for each cancer type from the SEER
database. The population gender for each cancer type
was chosen to be the same as that reported in the
corresponding epidemiological study of radiotherapy
ERRs. For example, only male patients were studied to
determine ERR for bladder cancer following radio-
therapy for testicular cancer, so the male-speciﬁc
background incidence for bladder cancer was ﬁtted.
Gender-averaged background incidence was used
where both sexes were studied after radiotherapy,
such as in the case of CNS tumors. The relevant age at
exposure Tx was deﬁned as Tx = max (0, T–L ), where
T is the age at cancer incidence reported by SEER. It
was assumed that L = 10 years, but the results were
not substantially sensitive to variations of L in the
plausible range of 3–15 years, provided the other
parameters were adjusted correspondingly. This ﬁtting
step generated values for parameters a, b, and c for
each cancer type.
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1232. The best-ﬁt value of b was used in a second round of
ﬁtting the model-generated ERRs to radiation-induced
ERR data sets: both the comparatively low-dose ERR/
Gy from Japanese atomic bomb survivors, and the
high-dose radiotherapy-induced ERR data for each
cancer type. Mean age at exposure and time since
exposure values from the references cited above were
used for each epidemiological high-dose radiotherapy
data set. Moderate variations in these numbers pro-
duced some corresponding changes in the best-ﬁt
parameter values, but did not alter the main conclu-
sions. This second round of ﬁtting generated values for
the remaining adjustable parameters X, Y, d, and Z.
This two-step procedure was chosen because the back-
ground cancer incidence data have much greater statistical
precision, due to larger sample sizes, compared with ERR
estimates. Therefore, it was deemed advantageous to set
the values for a, b, and c from background data, before
ﬁtting the radiation-induced risks. Only parameter b is
shared by the equations for background and radiation-
induced cancer risks.
Estimation of parameter uncertainties
For each data set (SEER, atomic bomb survivors, and
second cancers), 100 synthetic data sets were generated by
Monte-Carlo simulation. For the SEER data, the simula-
tions were based on the Poisson distribution (which is well
approximated by the Normal distribution because the
observed number of cancer cases for each 5-year age cat-
egory is typically [100). For the atomic bomb survivors
data, the simulations were based on the Chi-squared dis-
tribution with one degree of freedom, because this distri-
bution was used by (Preston et al. 2007) to generate
conﬁdence intervals for their summary ERR values, which
are used here. For the second cancer data, the Poisson
distribution was used.
We ﬁtted the model (the hazard function for background
cancer incidence) ﬁrst to the simulated SEER data, gen-
erating a distribution of values for each background
parameter (parameters a, b, and c). For each parameter,
95% CI were generated based on these distributions. Then,
the model-predicted ERR expression was ﬁtted simulta-
neously to the simulated atomic bomb and second cancer
data sets, generating distributions and 95% CI for the
remaining adjustable parameters.
Results
The best-ﬁt model parameters and predictions are shown in
Tables 1 and 2 and Figs. 1, 2, 3. In general, the ﬁts were
adequate, particularly considering the uncertainties in the
data and the biologically motivated constraints placed on
four parameters (a, b, k, L). We next highlight some fea-
tures of the results on background cancers (Fig. 1), cancers
in atomic bomb survivors (Fig. 2) and second cancers after
radiotherapy (Fig. 3).
Special features of the results
The cancer type-speciﬁc background incidence rates were
usually ﬁtted well, using the three relevant parameters a, b,
and c (Fig. 1). At older ages some of the ﬁts were quali-
tatively better than those produced by the commonly used
two-stage clonal expansion (TSCE) model with the same
number of parameters (e.g. Heidenreich et al. 2007). The
reason for this difference is that the TSCE model generates
an incidence hazard function that asymptotically levels off
at old age at some high value (e.g. Denes and Krewski
Table 2 Best-ﬁt parameter values for radiation-induced excess relative risk (ERR) of all analyzed cancer types
Cancer X (years 9 Gy
-1) Y (Gy
-1) d 9 10
-3 (years
-1) log10 Z a (Gy
-1), b (Gy
-2) k (day
-1)
Stomach 6.53 (1.94, 13.5) 0.120 (0.089, 0.145) 0.206 (0.00, 0.364) 3.58 (2.65, 3.66) 0.25, 0.025 0.05
Lung 0.860 (0.276, 10.5) 0.387 (0.279, 0.690) 9.49 (1.38, 23.3) 4.99 (3.80, 5.56) 0.25, 0.025 0.05
Colon 1.71 (0.010, 9.63) 0.872 (0.465, 1.39) 0.572 (0.00, 3.01) 0.301 (0.00, 0.628) 0.25, 0.025 0.10
Rectum 2.40 (0.048, 7.20) 0.0717 (0.041, 0.246) 0.0193 (0.00, 1.54) 2.09 (0.978, 3.05) 0.25, 0.025 0.10
Pancreas 3.12 (0.069, 10.7) 0.107 (0.073, 0.370) 0.019 (0.00, 28.6) 3.23 (2.73, 4.09) 0.25, 0.025 0.10
Bladder 0.151 (0.102, 13.1) 0.626 (0.439, 0.878) 1.68 (0.00, 3.92) 1.96 (1.72, 2.13) 0.25, 0.025 0.05
Breast 4.75 (0.880, 10.1) 0.938 (0.653, 1.11) 3.05 (0.00, 3.08) 6.65 (5.47, ?) 0.25, 0.050 0.05
CNS 1.45 (0.046, 13.5) 0.620 (0.273, 1.15) 0.0316 (0.00, 20.5) 5.69 (4.27, ?) 0.25, 0.025 0.10
Thyroid 34.4 (5.40, 69.1) 0.237 (0.097, 0.809) 0.0156 (0.00, 0.369) 4.03 (3.02, 6.15) 0.30, 0.030 0.05
Parameter interpretations are: X radiation-induced initiation constant, Y radiation-induced promotion constant, d parameter for homeostatic
regulation of the number of pre-malignant stem cells per niche, Z carrying capacity for pre-malignant stem cells per niche, a, b stem cell
inactivation constants by radiation, k maximum net stem cell repopulation rate
The numbers in parentheses represent the 95% conﬁdence intervals for the corresponding parameter
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1231996), whereas the recent data from SEER suggest the
incidence of many cancers to decrease at the oldest
recorded ages. Our model is based on the assumption that
this decrease is due to age-dependent loss of stem cell
function (senescence), although other causes, e.g. quality
of diagnosis, birth-date cohort effects, or selection due to
populations with heterogeneous risks (‘‘frailty’’), cannot be
excluded.
Our model did not ﬁt the background incidence of CNS
cancers as well as that of other cancer types, because it
underestimated the data at young ages, below 40 years.
The incidence of CNS cancers at young ages may be
produced by a different biological mechanism than that at
older ages, and/or occur in a sub-population of genetically
predisposed individuals, and therefore may require a sep-
arate set of parameters.
As expected, the parameter proportional to the sponta-
neous initiation rate (a) varies by orders of magnitude for
the different cancer types, since the observed incidence
rates for these cancers are also very different. The rates (b)
for replication of pre-malignant stem cell niches, however,
are much more tightly dispersed; most fall in the range of
0.2–0.46 years
-1. The values qualitatively agree with the
best-ﬁt clonal expansion rates (birth minus death) found
using the TSCE model (e.g. Heidenreich et al. 2007), and
support the intuitive idea that pre-malignant stem cells
have only a small net growth advantage over normal ones,
so that their number increases only on the scale of years to
decades. Numerically, the estimates of b tend to be
somewhat larger than the net clonal expansion rates in the
TSCE model, because in our formalism clonal growth by
niche replication is partially offset by stem cell senescence
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Fig. 1 Best-ﬁt model predictions for US background incidence of each cancer type, from the SEER database. The sex of each population and the
model parameter values are listed in Table 1. Error bars represent 95% conﬁdence intervals
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123(parameter c), which reduces the number of potentially
carcinogenic stem cells in each niche.
Altering the model assumptions by postulating that more
than one mutation is necessary to initiate a stem cell results
in some reduction in the best-ﬁt values of b. This is
expected because the number of mutational stages and the
rate of clonal expansion have somewhat similar effects on
the predicted age-dependent hazard function (e.g. Kopp-
Schneider and Portier 1991; Little and Wright 2003; Little
and Li 2007), so that increasing the ﬁrst results in a cor-
responding decrease in the second. However, the model
variant with more than two mutational stages did not ﬁt the
data substantially better than the default two-stage for-
malism (not shown), and was not used because it requires
an extra adjustable parameter (i.e. the number of mutations
necessary for stem cell initiation).
The stem cell senescence parameter (c) is also relatively
tightly distributed for most cancers, such that c/b = 6 -
7 9 10
-3 years
-1. These ﬁndings support an intuitive
picture that the senescence rate is roughly proportional to
the cell division rate—hence, the constancy of the c/b ratio.
The ERR/Gy estimates from Japanese atomic bomb
survivors at age 70, as function of age at exposure, were
also ﬁtted quite well for all cancer types (Fig. 2). In the
context of our model, the shape of the dependence of
radiation-induced ERR on age at exposure provides
insight into whether this ERR is dominated by initiation
or promotion. As noted in the accompanying article
(Shuryak et al. 2009), initiation-driven ERR should
decrease markedly with age at exposure. In contrast,
promotion-driven ERR should be relatively constant as
function of age.
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Fig. 2 Best-ﬁt model predictions for sex-adjusted ERR/Gy estimates
from Japanese atomic bomb survivors for each cancer type, from
(Preston et al. 2007). The error bars represent 95% conﬁdence
intervals. For rectal, pancreatic and CNS cancers, the ERR/Gy
estimates had no statistically-signiﬁcant age-dependence, as shown by
dashed horizontal lines in the corresponding ﬁgure panels. The sex of
each population and the parameter values are listed in Table 1
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123The atomic bomb survivor data (Preston et al. 2007)
suggest that a substantial decrease in ERR/Gy with age at
exposure occurs only for stomach and thyroid cancers,
among those analyzed here. Consistently with the above
arguments, the lower bounds of the 95% CI for the radia-
tion-induced initiation parameter X for these particular
cancers were substantially[0 (Table 2). For the seven other
cancer types, ERR/Gy appears to be independent of age at
exposure, or even to increase at older ages. For these can-
cers, the lower bounds of the 95% CI for parameter X were
approaching zero. Indeed, restricting X to zero worsened the
model ﬁt only marginally in many of these cases.
The ERR/Gy data for lung cancer stand out from the
others by apparently increasing with age at exposure
(Fig. 2). This may be due to residual confounding by the
rapid changes in smoking rates in Japan (Preston et al.
2007). However, since our model does not include the
effects of smoking, the trend in the data points was attrib-
uted by the model to effects of both age at exposure and
time since exposure: because the ERR/Gy was measured at
a ﬁxed age of 70, age at exposure and time since exposure
were not independent—their sum had to equal 70. In the
context of our model, an apparent increase in ERR with age
at exposure was interpreted as a decrease in ERR with time
since exposure, which occurs if radiation-induced promo-
tion is reversible due to homeostatic regulation of the
number of pre-malignant cells per niche, i.e. if parameter d
is[0. This explains why the best-ﬁt value for d was[0 for
lung cancer, and the lower bound for its 95% CI was also[0
(Table 2). In contrast, the lower bounds for the 95% CI for d
were zero for the other cancers, and setting d to zero did not
alter the ﬁts substantially in these cases.
Recent analyses of atomic bomb survivor data (Little
2009; Walsh 2009) suggest that an apparent increase in
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Fig. 3 Best-ﬁt model predictions for high-dose fractionated radio-
therapy ERRs for each cancer type. The error bars represent 95%
conﬁdence intervals. The corresponding references for each data set
are listed in the ‘‘Methods’’ section. The sex of each population and
the parameter values are listed in Table 1
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123ERR/Gy for the oldest ages at exposure may occur for
several other cancer types in addition to lung cancer. This
phenomenon can be due to multiple factors, e.g. activation
of microscopic dormant tumors by radiation. The expla-
nation given by the current model for lung cancer is also a
plausible hypothesis for explaining these new data for other
cancers.
The best ﬁts to the high-dose radiotherapy-induced
ERRs were also generally adequate (Fig. 3). The ﬁts to
colon and bladder cancer data were the poorest. This was
due to an inherent inconsistency in the data between ERR/
Gy from the Japanese atomic bomb survivors, and ERR for
multiple-Gy radiotherapy: at 1 Gy, the mean ERR/Gy for
colon cancer is 0.61–0.75 (atomic bomb survivor data,
Fig. 2), whereas at 6.9 Gy it is 0.03 and at 13.9 Gy it is
0.082 (second cancer data, Fig. 3). The same pattern can be
seen by comparing other recent second cancer data sets
(e.g. Chaturvedi et al. 2007) with atomic bomb survivor
data. In general, the risk estimates of radiotherapy-induced
colon cancer from different sources are highly variable
(e.g. Inskip et al. 1990; Lundell and Holm 1995; Carr et al.
2002). Because of the more than tenfold inconsistency in
the ERR/Gy slopes at different doses using the data sets we
selected, our model overestimates the ERR at radiothera-
peutic doses. A better ﬁt to the high-dose data could be
produced only by allowing unrealistically high cell inac-
tivation, e.g. a[1.0 Gy
-1. A qualitatively similar picture
was found for bladder cancer, where the ERR observed
after [20 Gy of fractionated radiotherapy is roughly
comparable to the ERR seen at 1 Gy in the atomic bomb
survivors.
For the other seven cancers analyzed here, the atomic
bomb survivors data at 1 Gy and the high-dose radiother-
apy data produced relatively similar ERR/Gy slopes, at
least at doses \20 Gy, so the model ﬁts are substantially
better (Fig. 3). There is a tendency to underestimate the
risk at very high doses for some cancers, but this is prob-
ably due to the default values of a and b being too high for
stem cells—better ﬁts were produced by lowering a to say
0.15 Gy
-1.
Discussion
We have presented a biologically motivated mathematical
model of background and radiation-induced cancer risk,
and applied it to data on nine solid adult-onset second
cancer types. The model takes into account initiation,
inactivation, and repopulation of target stem cells (iir
processes) throughout the comparatively short-term period
of radiotherapy and recovery by a stochastic formalism.
This formalism is integrated with a deterministic long-term
two-stage carcinogenesis model, which follows the kinetics
of pre-malignant stem cells throughout the entire human
lifetime, before and after radiation exposure.
Such an approach, unifying short- and long-term mod-
els, has some advantages over currently existing methods,
as discussed in the previous article. Brieﬂy, our model
allows mechanistic risk predictions to be made at high
radiotherapeutic doses as well as at low doses, can track the
age and time dependencies of risk mechanistically, and is
qualitatively better at describing background cancer inci-
dence at old ages than the commonly used two-stage clonal
expansion (TSCE) model, with the same number of
adjustable parameters. Radiation-induced risks are calcu-
lated analytically, using plausible assumptions about
underlying biology.
The current model is an improvement over our previous
models. For example, in our deterministic solid tumor
model (Sachs and Brenner 2005), the shape of the ERR
dose response was determined by the relative proliferation
rate of pre-malignant stem cells compared with normal
ones—parameter r. To describe the data, r had to be
smaller than 1, e.g. 0.8, implying that pre-malignant cells
proliferate more slowly than normal ones, at least over the
short term, i.e. during radiotherapy and for some weeks
afterwards. Such an interpretation is at odds with the long-
term tendency of pre-malignant cells to clonally expand. In
our stochastic analysis of the same problem (Sachs et al.
2007), this inconsistency was removed, and a ﬁt to the data
was possible even if pre-malignant cells were assumed to
proliferate as fast as, or faster than, their normal counter-
parts, i.e. r C 1. However, the stochastic algorithm
involved additional adjustable parameters. In the current
model, repopulation of pre-malignant cells during radio-
therapy is assumed to occur at the same rate as that of
normal ones, i.e. r = 1 implicitly. The reasoning is that any
proliferative advantage that pre-malignant cells have
manifests itself only on the scale of multiple years in
humans. The model describes the data adequately, so there
is no need for r to be smaller than 1, and no need for
additional parameters.
Our model applied to second cancer data can also pro-
vide some insight into the underlying biological mecha-
nisms of carcinogenesis. An important outcome of our
analysis is the ﬁnding that for many cancer types, radia-
tion-induced risk, especially at ages [20, may be domi-
nated by promotion, rather than initiation. Such an
important role of promotion in low-LET radiation-induced
risk for many cancers is consistent with the ﬁndings of
other authors using the TSCE model on Japanese atomic
bomb survivor data (e.g. Heidenreich et al. 2007). Our
results indicate that promotion is the dominant mechanism
of radiogenic risk for lung, colon, rectal, pancreatic, blad-
der, and CNS tumors; initiation and promotion both con-
tribute to stomach and breast cancer risk; and thyroid
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123cancer risk is dominated by initiation (see best-ﬁt param-
eter values in Table 1). For example, we estimated that a
1 Gy dose leads to almost a doubling in the number of
existing pre-malignant cells in the breast. Of course, this
conclusion about the importance of radiogenic promotion
is dependent on model assumptions, and needs to be tested
experimentally.
For most cancers analyzed here, promotion appears to
be permanent, i.e. pre-malignant niches are not reduced in
size or number over time after irradiation. However, a
gradual reduction in niche size after exposure, at a rate of
*1% per year, is suggested for lung cancer, and at a
slower rate for some other cancers. These ﬁndings indicate
that the radiation-induced hyper-proliferation of pre-
malignant cells may be either permanent, or transient,
depending on the organ.
The iir-based models in general, including the one
described here, produce a dose response that has the same
basic shape, with a maximum ERR at some intermediate
dose, as the shape generated by older linear–quadratic–
exponential (LQE) models, which neglected repopulation
by cell proliferation (Little 2001; Bennett et al. 2004; Dasu
et al. 2005). The main difference is in the dose range at
which the maximum occurs. Models without repopulation
predict that maximum ERR would occur at relatively low
doses (below 5 Gy), and at typical clinically used doses
(above 30 Gy) ERR would be essentially zero, due to the
inactivation of nearly all target stem cells. In iir models,
repopulation of both normal and pre-malignant stem cells
between dose fractions compensates for much of the inac-
tivation. Consequently, ERR peaks at much higher doses,
e.g. 20–60 Gy. This prediction is much more consistent
with the recent epidemiological data, which indicates that
ERR can remain substantial even at doses as high as 40–
50 Gy (e.g. Travis et al. 1996, 1997, 2002, 2003, 2005).
In the context of the model presented here, the radiation
dose at which ERR peaks is determined by the carrying
capacity for pre-malignant cells per niche, Z, in addition to
the cell killing parameters a and b and the repopulation rate
k. Physiologically, Z can be interpreted as an estimate for
the number of stem cells that contribute to repopulation
within a given location of the target organ. For most can-
cers analyzed here, the best-ﬁt values of Z (Table 2) sug-
gested that up to several thousand stem cells may cooperate
for local repopulation. The exceptions were breast and
CNS cancers, where the upper bound of the 95% CI for the
best-ﬁt value of Z is inﬁnity, suggesting that all the stem
cells in the entire organ may participate in repopulation
after irradiation.
The ability to reasonably predict cancer ERR at both
low and high radiation doses using a biologically based
mathematical model, incorporating formalisms for both
short-term (iir) and long-term processes, should enable this
model to be used for optimization of radiotherapy proto-
cols, by introducing second cancer risk as an additional
criterion. This can be done if a dose-volume histogram for
the protocol is available, as is usually the case (e.g.
Hodgson et al. 2007; Koh et al. 2007).
Almost by deﬁnition, all mathematical models are
greatly simpliﬁed representations of complex and incom-
pletely understood biological processes. Our model has the
main inherent drawbacks of other two-stage and iir carci-
nogenesis formalisms; extension to more stages and pro-
cesses may improve biological realism, but at the cost of
extra parameters. For example, the model can be extended
by treating long-term clonal expansion stochastically
instead of deterministically, by incorporating more detailed
cell–cell interactions other than just a slowdown in net cell
proliferation after ﬁlling of a pre-malignant stem cell niche,
by allowing the number of pre-malignant cells at birth to be
greater than 0, by accounting for variability in the lag
period for the development of clinical cancer after the
appearance of the ﬁrst malignant cell, etc.
In the future, we intend to apply the model to additional
second cancer data sets, where only a single estimate of
radiation dose is available, but more information can be
gained about age/time dependencies of radiation-induced
risk. For example, some such studies with long follow-up
times and large numbers of patients (e.g. Chaturvedi et al.
2007; Brown et al. 2007) suggest that these age/time
dependencies may have different trends from the age/time
dependencies suggested by Japanese atomic bomb survi-
vors data, which is used here. Using data on older radio-
therapy protocols optimally will be an important step in
credibly projecting second cancer risks of current and
future protocols decades into the future.
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